帕博利珠单抗诱导的透明细胞肾细胞癌患者横纹肌溶解症：一例报告
Pembrolizumab-Induced Rhabdomyolysis in a Clear Cell Renal Cell Carcinoma Patient: A Case Report.
作者信息
Altermanini Mohammad, Ali Khaled, Alwassiti Wisam, Almohtasib Suliman, Omar Nabil E, Zafar Abdulaziz
机构信息
Internal Medicine, Hamad Medical Corporation, Doha, Qatar.
Community Medicine, Hamad Medical Corporation, Doha, Qatar.
出版信息
Case Rep Oncol. 2023 Aug 25;16(1):728-733. doi: 10.1159/000532100. eCollection 2023 Jan-Dec.
Pembrolizumab is one of the approved treatments for many types of cancer including clear cell renal cell carcinoma (ccRCC). It has improved the prognosis of renal cell carcinoma, yet has many possible immune-related side effects. We discuss a rare case of rhabdomyolysis in an ccRCC patient treated with pembrolizumab. The case was complicated with acute kidney injury and severe hypothyroidism, which can be attributed to pembrolizumab.
帕博利珠单抗是包括透明细胞肾细胞癌（ccRCC）在内的多种癌症的获批治疗药物之一。它改善了肾细胞癌的预后，但也有许多可能的免疫相关副作用。我们讨论了一例接受帕博利珠单抗治疗的ccRCC患者发生横纹肌溶解的罕见病例。该病例并发急性肾损伤和严重甲状腺功能减退，这可能归因于帕博利珠单抗。
Zotero 插件